Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 548

Sort by

Sort Order Select

Journal Articles

CLL cells are moved by the MARCKS brothers

Jan A. Burger

Blood (2021) 138 (7): 503–504.

https://doi.org/10.1182/blood.2021011650

Published: 2021

Journal Articles

CLL-IPI: valid in the era of oral inhibitors?

Nadine Kutsch

Blood (2021) 138 (2): 106–107.

https://doi.org/10.1182/blood.2021011937

Published: 2021

Journal Articles

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Susan M. Schwager, Connie E. Lesnick, Geffen Kleinstern, Daniel Van Dyke, Curtis A. Hanson, Esteban Braggio, Susan L. Slager, Tait D. Shanafelt

Blood (2021) 138 (2): 149–159.

https://doi.org/10.1182/blood.2020009813

Published: 2021

Includes: Supplemental data

Journal Articles

Familial patterns of hematologic precursors

Ola Landgren, Francesco Maura

Blood (2021) 137 (15): 1992–1993.

https://doi.org/10.1182/blood.2020010035

Published: 2021

Journal Articles

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Blood (2021) 137 (15): 2046–2056.

https://doi.org/10.1182/blood.2020006322

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Zhijian Cao, MD, Jun Ma, MD PhD

Blood (2019) 134 (Supplement_1): 5478.

https://doi.org/10.1182/blood-2019-126686

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq

Blood (2019) 134 (Supplement_1): 5217.

https://doi.org/10.1182/blood-2019-129134

Published: 2019

Journal Articles

Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Marcin M Machnicki, MSc, Patryk Górniak, Monika Pepek, MSc, Agnieszka Szymczyk, Elżbieta Iskierka-Jażdżewska, Pawel Steckiewicz, Aleksandra Bluszcz, Malgorzata Rydzanicz, PhD, Marek Hus, Rafal Ploski, MD PhD, Przemyslaw Juszczynski, Prof., MD PhD, Tomasz Stoklosa, MD PhD, Krzysztof Jamroziak, MD PhD, Bartosz Pula

Blood (2019) 134 (Supplement_1): 5456.

https://doi.org/10.1182/blood-2019-124693

Published: 2019

Journal Articles

Reduced Expression of the CD94/NKG2C NK Cell Receptor in Chronic Lymphocytic Leukemia (CLL) and CLL-like Monoclonal B-Cell Lymphocytosis (MBL)

Anna Puiggros, PhD, Gonzalo Blanco, PhD, Aura Muntasell, María Rodríguez-Rivera, Lara Nonell, Eulalia Puigdecanet, Magdalena Arnal, Xavier Calvo, MD PhD, Eva Gimeno, MD PhD, Eugenia Abella, Pau Abrisqueta, MD PhD, Francesc Bosch, MD PhD, José Yélamos, Ana Ferrer, MD PhD, Miguel Lopez-Botet, Blanca Espinet, PhD

Blood (2019) 134 (Supplement_1): 5457.

https://doi.org/10.1182/blood-2019-128055

Published: 2019

Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Blood (2019) 134 (Supplement_1): 4296.

https://doi.org/10.1182/blood-2019-128470

Published: 2019

Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey

Blood (2019) 134 (Supplement_1): 2571.

https://doi.org/10.1182/blood-2019-128872

Published: 2019

Journal Articles

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Brian Giacopelli, BS, Kari G. Chaffee, MS, Yue-zhong Wu, MSc, John C. Byrd, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 3022.

https://doi.org/10.1182/blood-2019-123564

Published: 2019

Journal Articles

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

Gonzalo Blanco, PhD, Anna Puiggros, PhD, Barbara Sherry, PhD, Lara Nonell, Eulalia Puigdecanet, Pui Yan Chiu, Yasmine Kieso, MSCR, Gerardo Ferrer, PhD, Magdalena Arnal, María Rodríguez-Rivera, Eva Gimeno, MD PhD, Eugenia Abella, Kanti R Rai, MD, Pau Abrisqueta, MD PhD, Xavier Calvo, MD PhD, Francesc Bosch, MD PhD, Ana Ferrer, MD PhD, Nicholas Chiorazzi, MD, Blanca Espinet, PhD

Blood (2019) 134 (Supplement_1): 3027.

https://doi.org/10.1182/blood-2019-122038

Published: 2019

Journal Articles

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Wei Xu, MD PhD, Jie Jin, MD PhD, Keshu Zhou, MD, Li Wang, MD, Huayuan Zhu, Jiejing Qian, Jianying Huang, Fuling Zhou, MD, Xiaohong Xu, Zhiqiang Wang, Wei Guo, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 4000.

https://doi.org/10.1182/blood-2019-126707

Published: 2019

Journal Articles

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Chan Y. Cheah, Nicholas Wickham, MBBS, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Katharine L Lewis, FRCPath, MRCP, MBBS, Chi-Hung Hui, MBBS, Pek Sang Tang, MBBS, Tejasvi Turpuseema, Hari P Miskin, MSc, Jian-Ping Tang, PhD, Emmanuel Normant, PhD, Alejandro D. Ricart, MD, Constantine S. Tam, MBBS (Hons), MD

Blood (2019) 134 (Supplement_1): 4001.

https://doi.org/10.1182/blood-2019-126951

Published: 2019

Journal Articles

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Michele Merli, MD, Benedetta Bianchi, MD, Lorenza Bertù, Andrea Ferrario, MD, Barbara Mora, Silvia Uccella, MD, Daniela Furlan, Maria Grazia Tibiletti, Simona Cattaneo, Fausto Sessa, Prof., Francesco Passamonti, Prof.

Blood (2019) 134 (Supplement_1): 4017.

https://doi.org/10.1182/blood-2019-130288

Published: 2019

Journal Articles

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Peter Hillmen, MD PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O'Brien, MD, Lugui Qiu, MD PhD, Tommi Salmi, MD, James Hilger, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 4307.

https://doi.org/10.1182/blood-2019-124213

Published: 2019

Journal Articles

Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?

Gonzalo Blanco, PhD, Anna Puiggros, PhD, Barbara Sherry, PhD, Lara Nonell, Xavier Calvo, MD PhD, Eulalia Puigdecanet, Pui Yan Chiu, Yasmine Kieso, MSCR, Gerardo Ferrer, PhD, Magdalena Arnal, María Rodríguez-Rivera, Eva Gimeno, MD PhD, Eugenia Abella, Kanti R Rai, MD, Pau Abrisqueta, MD PhD, Francesc Bosch, MD PhD, Ana Ferrer, MD PhD, Nicholas Chiorazzi, MD, Blanca Espinet, PhD

Blood (2019) 134 (Supplement_1): 3029.

https://doi.org/10.1182/blood-2019-122061

Published: 2019

Journal Articles

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

William J Archibald, MDCPA, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Curtis A. Hanson, MD, Wei Ding, MD PhD, Amber Koehler, PA-C, MS, Eli Muchtar, MD, Suzanne R. Hayman, MD, Saad S. Kenderian, MD, Jose F. Leis, MD PhD, Yucai Wang, MD PhD, Amie Fonder, PA-C, MS, Min Shi, MD PhD, Daniel L. Van Dyke, PhD, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3037.

https://doi.org/10.1182/blood-2019-131154

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CLL cells are moved by the MARCKS brothers

CLL-IPI: valid in the era of oral inhibitors?

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Familial patterns of hematologic precursors

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq

Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Reduced Expression of the CD94/NKG2C NK Cell Receptor in Chronic Lymphocytic Leukemia (CLL) and CLL-like Monoclonal B-Cell Lymphocytosis (MBL)

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only